American Society of Hematology

The American Society of Hematology (ASH) leads the world in promoting and supporting clinical and scientific hematology research through its many innovative award programs, meetings, publications, and advocacy efforts.

ASH Research Agenda

ASH’s roadmap for the prioritization of research support across the hematology community

ASH Research Registry

A research-focused registry that will harness the power of big data to conquer blood diseases worldwide

Sickle Cell Priorities

The Society's top research and training priorities for sickle cell disease and sickle cell trait for the next five years

Research Recommendations

Recommendations, priorities, and action items for various hematology-related initiatives and areas of research

Programs and Awards

Awards and programs offered by ASH to support clinical and scientific hematology research

Precision Medicine Initiative

An initiative to improve genomic profiling of hematologic diseases and identify strategies to improve the use of molecular data in clinical care, research, and education

Blood

Blood is an official journal of the American Society of Hematology and the most cited peer-reviewed publication in the field. It is published weekly every Thursday, except for the last week in December. Additionally, an ASH annual meeting abstracts issue is published annually in November.

Blood Advances

Blood Advances, the first journal to join the Blood family in 70 years, is a peer-reviewed, online only, open access journal. Under the direction of founding editor-in-chief Robert Negrin, MD, the inaugural issue made it's debut in November 2016.

View all Diffusion articles
  • CAR T-cell Therapy: An Update on Coverage and Reimbursement

    ASH continues to advocate for adequate coverage and reimbursement for chimeric antigen receptor T-cell (CAR-T) therapy. In early August, the Centers for Medicare and Medicaid Services (CMS) finalized policies impacting both reimbursement of and coverage for CAR-T therapy. The final Inpatient Prospective Payment System (IPPS) rule, published on August 2, and the final Decision Memo for CAR T-cell Therapy for Cancers, issued August 7.

  • 2018 ASH Advocacy Activities

    ASH continues to increase its efforts to expand and enhance the Society’s reach. NIH funding, efforts to ensure patient access to drugs, and sickle cell disease were top priorities on ASH’s advocacy agenda in 2018.

  • 2018 ASH Advocacy Efforts Related to Sickle Cell Disease and Sickle Cell Trait

    ASH continues to invest in and explore the important actions needed to make a significant difference in sickle cell disease (SCD) access to care, research, and global issues. Learn about the major advocacy-related initiatives undertaken by ASH in 2018.

  • 2018 ASH Advocacy Efforts to Ensure Patient Access to Care

    In 2018, ASH worked to ensure patient access to care through a number of methods including ensuring drug access, pain management-related issues, and the Affordable Care Act.

View all policy news
back to top